MacroGenics Files 8-K on Security Holder Vote Matters

TL;DR

MGNX filed an 8-K, shareholders are voting on something important.

AI Summary

On May 21, 2025, MacroGenics, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in Delaware with its principal executive offices in Rockville, Maryland, is involved in the pharmaceutical preparations industry. Its common stock is traded on the Nasdaq Global Select Market under the ticker symbol MGNX.

Why It Matters

This filing signals that MacroGenics is engaging its shareholders on important corporate decisions, which could impact the company's strategic direction and future performance.

Risk Assessment

Risk Level: low — The filing is procedural and relates to a shareholder vote, not an immediate financial event or significant operational change.

Key Players & Entities

• MACROGENICS, INC. (company) — Registrant
• May 21, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Rockville, Maryland (location) — Address of Principal Executive Offices
• MGNX (ticker) — Trading Symbol for Common Stock
• Nasdaq Global Select Market (exchange) — Exchange where Common Stock is registered

FAQ

From the Filing

0001125345-25-000075.txt : 20250522 0001125345-25-000075.hdr.sgml : 20250522 20250522160056 ACCESSION NUMBER: 0001125345-25-000075 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250521 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250522 DATE AS OF CHANGE: 20250522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MACROGENICS INC CENTRAL INDEX KEY: 0001125345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36112 FILM NUMBER: 25976945 BUSINESS ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: Rockville STATE: MD ZIP: 20850 BUSINESS PHONE: 301-251-5172 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 mgnx-20250521.htm 8-K mgnx-20250521 0001125345 FALSE 0001125345 2025-05-21 2025-05-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported):  May 21, 2025   MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer  Identification No.) 9704 Medical Center Drive Rockville, Maryland 20850 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code:  ( 301 ) 251-5172   Not applicable  (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share MGNX Nasdaq Global Select Market   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07 Submission of Matters to a Vote of Security Holders. MacroGenics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders on May 21, 2025. A total of 52,004,843 shares of the Company's common stock were present or represented by proxy at the meeting, which represented approximately 82% of the Company's 63,090,323 shares of common stock that were outstanding and entitled to vote at the meeting as of the record date of March 24, 2025. Stockholders considered the four proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 11, 2025 (the "Proxy Statement"). Proposal 1 . The election of four nominees to serve as Class III directors, each for a term of three years. All director nominees were elected. The voting resul